Novartis AG (NYSE: NVS; SIX: NOVN) is a Swiss multinational pharmaceutical corporation headquartered in Basel, Switzerland. Founded on December 20, 1996, through the merger of Ciba-Geigy and Sandoz, Novartis operates as a pure-play innovative medicines company following strategic divestitures of its generics (Sandoz, 2023) and eye care (Alcon, 2019) divisions.
As of 2025, Novartis employs approximately 75,267 to 78,742 associates worldwide, with variation reflecting different measurement methodologies and timing within the year. This represents a significant reduction from the historical peak of over 129,900 employees in 2018, primarily due to the Sandoz separation.
| Metric | FY 2025 (USD millions) | FY 2024 (USD millions) | Growth (USD / cc) |
|---|---|---|---|
| Net Sales | 54,532 | 50,317 | +8% / +8% |
| Operating Income (IFRS) | 17,644 | 14,544 | +21% / +25% |
| Net Income (IFRS) | 13,967 | 11,939 | +17% / +19% |
| Core Operating Income | 21,889 | 19,494 | +12% / +14% |
| Core Net Income | 17,411 | 15,755 | +11% / +12% |
| Free Cash Flow | 17,596 | 16,253 | +8% |
| Core Operating Margin | 40.1% | 38.7% | +140 bps |
Note: "cc" denotes constant currency growth. Core figures are non-IFRS adjusted metrics.
Novartis has positioned itself as a focused innovative medicines company with leadership across four core therapeutic areas:
The company prioritizes four key geographic markets: United States, China, Germany, and Japan, which collectively represent the majority of growth potential.
Novartis upgraded its medium-term guidance in 2025, projecting:
For 2026 specifically, Novartis expects low single-digit sales growth despite facing its largest patent expiry event in company history (~$4 billion revenue impact from generic competition on Entresto, Promacta, and Tasigna), with stronger recovery anticipated in H2 2026 and 2027+.
Forward-Looking Disclaimer: This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section, including but not limited to: patent expiries and generic competition, regulatory developments, clinical trial outcomes, competitive pressures, pricing and reimbursement challenges, foreign exchange fluctuations, manufacturing and supply chain disruptions, acquisition integration risks, and general economic conditions.
Novartis was formed on December 20, 1996, through the merger of two Swiss pharmaceutical giants: Ciba-Geigy and Sandoz. The company name derives from the Latin novae artes, meaning "new skills," reflecting its innovation-focused mission.
The predecessor companies trace their roots back over 250 years:
Ciba and Geigy merged in 1970 to form Ciba-Geigy, creating one of the world's largest chemical and pharmaceutical companies.
The Ciba-Geigy and Sandoz merger was announced on March 7, 1996, and officially completed on December 20, 1996, creating a pharmaceutical powerhouse valued at approximately $30 billion with headquarters in Basel, Switzerland. The merger combined complementary strengths: Ciba-Geigy's pharmaceutical prowess with Sandoz's expertise in generics and nutrition.
| Year | Milestone |
|---|---|
| 1996 | Novartis AG founded through Ciba-Geigy and Sandoz merger; becomes one of the world's largest pharmaceutical companies |
| 2000 | Divested agribusiness to form Syngenta (joint venture with AstraZeneca); American Depositary Shares (ADSs) listed on NYSE |
| 2002 | Established Novartis Institutes for BioMedical Research (NIBR) in Cambridge, Massachusetts, consolidating global R&D operations |
| 2003 | Revived Sandoz brand for generics division; acquired Mead Johnson nutrition business |
| 2005 | Sandoz acquired Hexal (Germany) and Eon Labs (US) for $8.29 billion, becoming global generics leader |
| 2010 | Introduced first gene therapy for a genetic disease, pioneering cell and gene therapy platforms |
| 2018 | Vasant (Vas) Narasimhan appointed CEO (February 1, 2018), succeeding Joseph Jimenez |
| 2019 | Spun off Alcon eye care division as standalone company (April 2019) |
| 2023 | Completed spin-off of Sandoz generics division (October 2023), becoming pure-play innovative medicines company |
| 2024 | Acquired MorphoSys for oncology pipeline expansion (February 2024) |
| 2025 | Announced Avidity Biosciences acquisition to enhance RNA therapeutic capabilities (expected closing H1 2026) |
Novartis AG is a publicly traded company listed on:
| Shareholder Category | Percentage of Shares |
|---|---|
| Individual Investors | 57% |
| Institutional Investors | 38% |
| Other Entities | 5% |
As of December 31, 2024, and October 2025 SEC filings, major institutional investors include:
| Institution | Approximate Holding |
|---|---|
| BlackRock, Inc. | 5-10% of share capital |
| Dodge & Cox | Significant holder |
| Primecap Management Co/CA | Significant holder |
| Norges Bank (Norwegian Government Pension Fund) | 2.3% as of Dec 31, 2024 |
| Vanguard PRIMECAP Fund | Significant holder |
| Morgan Stanley | Significant holder |
As of October 2025, approximately 1,563 institutional owners filed disclosures with the SEC, collectively holding 140,189,898 shares.
Following the March 6, 2026 Annual General Meeting, the Board consists of 12 members:
| Director | Role | Notes |
|---|---|---|
| Giovanni Caforio | Chairman | Re-elected; became Chairman in 2025; former Bristol Myers Squibb CEO |
| Simon Moroney | Vice Chairman | Re-elected |
| Nancy C. Andrews | Governance & Nominating Committee Chair | Re-elected |
| Patrice Bula | Lead Independent Director | Re-elected |
| Bridgette Heller | Independent Non-Executive Director | Re-elected |
| Frans van Houten | Independent Non-Executive Director | Re-elected |
| Ton Büchner | Independent Non-Executive Director | Re-elected |
| Ana de Pro Gonzalo | Independent Non-Executive Director | Re-elected |
| Liz Doherty | Director | Re-elected |
| John D. Young | Independent Non-Executive Director | Re-elected |
| Charles Swanton | Director | Newly elected at 2026 AGM |
| Elizabeth McNally | Director | Re-elected; newly elected to Compensation Committee |
Note: Daniel Hochstrasser did not stand for re-election at the 2026 AGM.
The following additional Executive Committee members are confirmed as of early 2026:
Not publicly confirmed: Specific names and titles for therapeutic area heads (oncology, immunology, cardiovascular, neuroscience) and franchise P&L owners are not publicly disclosed by Novartis as of March 2026.
One confirmed therapeutic area leader:
| Product | Indication(s) | FY 2025 Revenue (USD millions) | Growth (cc) | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner |
|---|---|---|---|---|---|---|
| Kisqali (ribociclib) | HR+/HER2- breast cancer | ~5,300 (est.) | +57% FY, +44% Q4 | Protected to ~2030s | $10B+ | Not publicly confirmed |
| Pluvicto | PSMA+ mCRPC | 1,994 | +42% FY, +70% Q4 | Orphan exclusivity + patents | $3-10B | Not publicly confirmed |
| Scemblix (asciminib) | CML-CP | ~1,600 (est.) | +85% FY, +87% Q4 | Long exclusivity runway | $4B+ | Not publicly confirmed |
| Tasigna (nilotinib) | CML | Declining | Negative | US LOE 2026 | Legacy product | Not publicly confirmed |
| Promacta/Revolade | ITP, SAA, HCV-related | Declining significantly | -27% FY, -63% Q4 | US generic competition 2025-2026 | Legacy product | Not publicly confirmed |
| Product | Indication(s) | FY 2025 Revenue (USD millions) | Growth (cc) | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner |
|---|---|---|---|---|---|---|
| Cosentyx (secukinumab) | PsO, PsA, AS, HS | ~6,700 (est.) | +8% FY, +11% Q4 | US primary patent expired Aug 2025; secondary to 2035-2036 | Sustained blockbuster | Not publicly confirmed |
| Product | Indication(s) | FY 2025 Revenue (USD millions) | Growth (cc) | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner |
|---|---|---|---|---|---|---|
| Entresto | Heart failure (HFrEF, HFpEF) | 7,750 (FY) | -2% FY, -45% Q4 | US generic competition started 2025 | Declining rapidly | Not publicly confirmed |
| Leqvio (inclisiran) | Hypercholesterolemia, ASCVD | ~335 (Q4 annualized est.) | +46% FY | Approved 2021; long exclusivity | Blockbuster potential | Not publicly confirmed |
| Product | Indication(s) | FY 2025 Revenue (USD millions) | Growth (cc) | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner |
|---|---|---|---|---|---|---|
| Kesimpta (ofatumumab) | Relapsing MS | 4,400 (FY) | +36% FY, +27% Q4 | Approved 2020; long exclusivity | Multi-blockbuster ($5B+) | Not publicly confirmed |
Indications: Approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in combination with endocrine therapy, covering both advanced/metastatic disease and early-stage breast cancer (adjuvant setting).
Revenue & Growth:
Market Position: Kisqali is Novartis's fastest-growing major product, benefiting from early breast cancer label expansion (NATALEE trial data showing 28% reduction in recurrence risk over 5 years) and strong uptake in US market with oncologists preferring Kisqali over competitors (Ibrance, Verzenio) due to efficacy and safety profile.
Peak Sales Potential: Upgraded to $10B+ (from prior $8B+ target) based on expanded indications and market penetration.
Indications: Approved for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Regulatory filing pending for pre-taxane use (anticipated H1 2025 decision).
Revenue & Growth:
Market Position: Pluvicto is a groundbreaking radioligand therapy targeting PSMA (prostate-specific membrane antigen), representing a paradigm shift in mCRPC treatment. Strong uptake driven by efficacy in heavily pre-treated patients and limited competition (first-in-class PSMA-targeted radioligand therapy).
Peak Sales Potential: $3-10 billion, with upper end contingent on expanded earlier-line use and geographic expansion.
Indications: Approved for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) in patients previously treated with two or more tyrosine kinase inhibitors (TKIs), and for patients with the T315I mutation. Recently approved in Europe for first-line use (2025).
Revenue & Growth:
Market Position: Scemblix is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, offering a novel mechanism distinct from ATP-competitive TKIs. Superior efficacy vs. bosutinib in treatment-experienced patients and favorable tolerability profile enabling treatment-free remission strategies.
Peak Sales Potential: Upgraded to $4B+ (from prior $3B+ target) reflecting first-line expansion and CML market leadership potential.
Indications: Approved for relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Revenue & Growth:
Market Position: Kesimpta is a self-administered, once-monthly subcutaneous anti-CD20 monoclonal antibody competing in the high-efficacy MS therapy segment. Differentiation vs. infusion-based therapies (Ocrevus, Tysabri) via convenient at-home administration.
Peak Sales Potential: Multi-blockbuster potential ($5B+) as market share grows in high-efficacy MS segment.
Indications: Approved for plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and hidradenitis suppurativa (HS).
Revenue & Growth:
Market Position: Cosentyx is the leading IL-17A inhibitor, offering best-in-class efficacy across multiple immune-mediated inflammatory diseases. Volume growth across all indications with recent hidradenitis suppurativa approval expanding addressable market.
Patent Status: US primary patent expired August 2025; however, secondary patents extend to 2035-2036, potentially delaying full biosimilar competition. EU expiry expected ~2029-2030.
Based on CEO Vas Narasimhan's earnings calls, investor presentations, and strategic communications throughout 2025 and early 2026, the following five drugs represent leadership's highest priorities:
| Drug | 2025 Revenue | Growth | Peak Sales Target | Strategic Importance |
|---|---|---|---|---|
| 1. Kisqali | ~$5.3B | +57% cc | $10B+ | Fastest-growing major product; example of "launch excellence" in NME commercialization |
| 2. Kesimpta | $4.4B | +36% cc | $5B+ | Transforming MS treatment paradigm through patient-centric innovation (at-home self-administration) |
| 3. Pluvicto | $2.0B | +42% cc | $3-10B | Platform technology for radioligand therapy (RLT) with expansion potential across oncology |
| 4. Scemblix | ~$1.6B | +85% cc | $4B+ | Best-in-class innovation with novel mechanism (STAMP inhibitor) and strong clinical differentiation |
| 5. Cosentyx | ~$6.7B | +8% cc | Sustained $6-7B | Sustained growth through indication expansion; critical revenue bridge during 2026 patent cliff |
Novartis maintains a robust pipeline of over 100 clinical projects, with emphasis on four core therapeutic areas and emerging technology platforms including radioligand therapy, gene & cell therapy, and xRNA.
| Asset | Mechanism | Indication | Phase | Expected Milestone |
|---|---|---|---|---|
| Remibrutinib | BTK inhibitor | Chronic spontaneous urticaria (CSU) | NDA submitted 2025 | Approval expected 2026 |
| Pelacarsen (TQJ230) | ASO targeting Lp(a) | Secondary CV prevention (high Lp(a) + CVD) | Phase 3 | Readout late 2025 / early 2026 |
| Abelacimab | Factor XI inhibitor | Stroke prevention in atrial fibrillation | Phase 3 | Event-driven readout 2026 |
| GIA632 | High-affinity IL-15 mAb | Atopic dermatitis, autoimmune diseases | Phase 3 | Event-driven readout 2026 |
| 225Ac-PSMA-617 | Actinium-225 PSMA radioligand | mCRPC post-Pluvicto | Phase 3 (PSMAction) | Readout ≥2029 |
| Pluvicto (pre-taxane) | Lu-177 PSMA radioligand | Pre-taxane mCRPC (supplementary) | Regulatory filing | Decision H1 2025/2026 |
Novartis operates globally with strategic focus on four priority markets: United States, China, Germany, and Japan.
| Region | FY 2024 Revenue (USD millions) | % of Total | FY 2025 Revenue (USD millions) | % of Total | Growth (cc) |
|---|---|---|---|---|---|
| United States | 23,300 | 46.3% | 23,300 | 42.7% | +10% YoY |
| Rest of World | ~27,017 | 53.7% | 31,232 | 57.3% | Estimated +15-20% |
| Total Net Sales | 50,317 | 100% | 54,532 | 100% | +8% |
Note: Novartis does not publicly disclose detailed geographic revenue breakdowns beyond US vs. Rest of World in recent quarterly and annual reports. The "Rest of World" figure includes Europe, China, Japan, and other markets.
| Therapeutic Area | Novartis Key Products | Major Competitors | Competitor Products |
|---|---|---|---|
| Oncology (Breast Cancer) | Kisqali | Pfizer, Eli Lilly | Ibrance (palbociclib), Verzenio (abemaciclib) |
| Oncology (Prostate Cancer) | Pluvicto | Limited (first-in-class) | AstraZeneca FPI-2265 (Phase 2/3), Lilly PNT2001 (Phase 1) |
| Oncology (CML) | Scemblix, Tasigna | BMS, Takeda, Pfizer | Sprycel (dasatinib), Iclusig (ponatinib), Bosulif (bosutinib) |
| Immunology (IL-17) | Cosentyx | Eli Lilly, UCB | Taltz (ixekizumab), Bimzelx (bimekizumab) |
| Neuroscience (MS) | Kesimpta | Roche, Biogen, Sanofi | Ocrevus (ocrelizumab), Tysabri (natalizumab), Lemtrada |
| Cardiovascular (Heart Failure) | Entresto (genericizing) | AstraZeneca, Boehringer Ingelheim | Farxiga (dapagliflozin), Jardiance (empagliflozin) |
Global Revenue Rankings (2024):
Competitive Strengths:
Critical Risk: Novartis faces its largest patent expiry event in company history in 2026, with an estimated ~$4 billion revenue impact from generic competition on key products:
Mitigation: Management projects low single-digit 2026 sales growth despite LOE, with stronger recovery in H2 2026 and 2027+ driven by new product growth (Kisqali, Kesimpta, Pluvicto, Scemblix, Leqvio).
Novartis reports in USD but generates revenue globally. Key exposures:
| Metric | Target | Commentary |
|---|---|---|
| Net Sales CAGR | 5-6% (constant currency) | Driven by priority brands and pipeline approvals |
| Core Operating Margin | 40%+ through 2027; return to 40%+ by 2029 | Temporary 1-2 pp dilution from Avidity acquisition |
| Return on Capital | ~9% target | Disciplined capital allocation |
| Free Cash Flow | Strong generation expected | 2025: $17.6B; support for dividends, buybacks, R&D |
Market Capitalization (as of March 10, 2026):
| Company | 2024 Revenue (USD billions) | Market Cap (March 2026) | EV/Sales | Growth Profile |
|---|---|---|---|---|
| Novartis | 50.3 | ~$300B | ~4.8x | 5-6% CAGR; patent cliff 2026 |
| Roche | 49.9-57.2 | ~$250-280B | ~4.5-5.0x | Low single-digit; mature portfolio |
| Pfizer | 58.5-63.6 | ~$170-190B | ~2.5-3.0x | Negative post-COVID; rebuilding |
| AbbVie | 54.3-56.3 | ~$320-350B | ~5.5-6.0x | Mid-single-digit; Humira offset by Skyrizi/Rinvoq |
| Eli Lilly | ~35-40 | ~$700-850B | ~15-17x | Double-digit; GLP-1 hypergrowth |
Novartis valuation (EV/Sales ~4.8x, P/E ~17-21x) is in-line with diversified Big Pharma peers like Roche and Merck, reflecting:
2025 Baseline: $54.5 billion
Major Growth Contributors (+$16-24B incremental by 2030):
Headwinds (-$6-7B by 2030):
2030 Revenue Estimate: $64.5-71.5B (midpoint ~$68B, ~4.5-5% CAGR)
Conclusion: Novartis's 5-6% CAGR target is achievable but requires strong execution on Kisqali, Pluvicto, Scemblix achieving peak sales targets, Leqvio positive ORION-4 outcomes data, and pipeline delivering 15+ approvals on time.
| Product | Indication(s) | US Exclusivity | EU Exclusivity | Key Risk | Impact Timeline |
|---|---|---|---|---|---|
| Entresto | Heart failure | LOE 2025 | LOE 2025-2026 | Generic competition started 2025 | CURRENT (-45% Q4 2025) |
| Promacta/Revolade | ITP, SAA, HCV | LOE 2025-2026 | LOE 2025-2026 | Generic competition started | CURRENT (-63% Q4 2025) |
| Tasigna | CML | LOE 2026 | LOE 2026 | Part of 2026 patent cliff | 2026 ($4B cliff) |
| Cosentyx | PsO, PsA, AS, HS | Primary expired Aug 2025; secondary to 2035-2036 | ~End of decade (2029-2030) | Biosimilar entry risk early 2030s | 2030+ |
| Kisqali | HR+/HER2- breast cancer | Protected ~2030s | Protected ~2030s | Medicare negotiations 2028 (pricing risk) | 2028 (IRA) |
| Pluvicto | PSMA+ mCRPC | Orphan + patents; long runway | Orphan + patents; long runway | Competitive radioligand therapies emerging | 2030s+ |
| Scemblix | CML-CP | Protected ~2030s-2040s | Protected ~2030s-2040s | Long exclusivity | 2035+ |
| Kesimpta | Relapsing MS | Protected ~2030s-2040s | Protected ~2030s-2040s | Long exclusivity | 2035+ |
Key Takeaways:
The following section evaluates each major Novartis drug for fit with Ada Patient Finder, assessing diagnostic delay, underdiagnosis rates, per-patient revenue, addressable patient populations, and Ada's ability to surface relevant conditions through symptom assessment.
| Product | Indication | Fit Score | Per-Patient Revenue (Net, US) | Addressable Pool (US) | Recommendation |
|---|---|---|---|---|---|
| Kesimpta | Relapsing MS | 7/10 | $41,500-$64,000/year | ~4,600-9,500 | GOOD FIT - Neurological symptom clustering |
| Cosentyx | PsA (in psoriasis) | 7/10 | $32,500-$41,500 US; $52K-$66K EU | ~232,000-348,000 | GOOD FIT - Musculoskeletal symptoms in psoriasis patients |
| Fabhalta | PNH | 5/10 | $180,000-$400,000/year | <100 | MARGINAL FIT - High revenue but rare disease |
| Entresto | Heart failure | 2/10 | Near zero (generic) | N/A | POOR FIT - Genericized |
| Kisqali | Breast cancer | 3/10 | $50,000-$75,000/year | <1,000 | POOR FIT - Screening-detected |
| Pluvicto | mCRPC | 3/10 | $78,000-$187,200/year | <500 | POOR FIT - Patients already in oncology care |
| Scemblix | CML | 3/10 | $40,000-$50,000 US | <500 | POOR FIT - CBC-detected |
| Leqvio | HeFH, ASCVD | 2/10 | $3,250-$5,970/year | Large (FH) but low revenue | POOR FIT - Very low per-patient revenue |
Indication: Relapsing forms of multiple sclerosis (RMS)
Diagnostic Delay: Median 2-14 months from symptom onset; 52.7% of MS patients experience diagnostic delays, with 28.7% attributed to physician-dependent factors.
Per-Patient Revenue: $41,500-$64,000 net per patient per year (US commercial, 50% gross-to-net)
Addressable Pool: ~4,600-9,500 delayed/undiagnosed MS patients in US
Ada's Ability to Surface MS: HIGH - MS presents with diverse but characteristic neurological symptoms that Ada's symptom checker can cluster and flag:
Pitch Hook: "Over half of multiple sclerosis patients experience diagnostic delays averaging 2-14 months from symptom onset, with 28.7% of delays attributed to physician factors like anchoring bias and misinterpretation of early symptoms. Ada Patient Finder can reduce this critical diagnostic window by identifying characteristic neurological symptom patterns—optic neuritis, limb numbness, balance disturbances—and directing patients to neurology evaluation before irreversible disease progression occurs. With Kesimpta representing $41,500-$64,000 in net annual revenue per patient and an estimated 4,600-9,500 delayed diagnoses in the US, this represents a high-value patient identification opportunity in a market where early treatment initiation is clinically and economically imperative."
Indication: Psoriatic arthritis (PsA) in patients with psoriasis
Diagnostic Delay: Average 1-2.5 years from symptom onset; up to 33-50% of PsA patients experiencing extended delays
Underdiagnosis: 15.5% of psoriasis patients have undiagnosed psoriatic arthritis
Per-Patient Revenue: $32,500-$41,500 US (below $50K threshold); $52,000-$66,400 EU/ex-US (exceeds threshold)
Addressable Pool: ~232,000-348,000 undiagnosed PsA patients in US psoriasis population
Ada's Ability to Surface PsA: HIGH - PsA symptoms Ada can surface:
Pitch Hook: "Psoriatic arthritis patients face diagnostic delays averaging 1-2.5 years from symptom onset, with 15.5% of psoriasis patients harboring undiagnosed PsA that silently erodes joints and quality of life. Delays beyond 6 months lead to progressively worse patient-reported outcomes, including higher rates of unacceptable symptoms, depression, and social limitations. Ada Patient Finder can dramatically reduce this window by identifying characteristic musculoskeletal patterns—joint swelling in hands and feet, heel pain, 'sausage digits,' nail changes—and prompting dermatologists and primary care providers to initiate rheumatology referral before irreversible joint damage occurs. With over 230,000-348,000 undiagnosed PsA patients in the US and Cosentyx representing $52,000-$66,400 net annual revenue per patient in EU markets, this represents a massive patient identification opportunity with profound clinical and economic value."
Deploy Ada Patient Finder for:
Do NOT deploy for:
This report cites 140 independent sources across Novartis official materials (annual reports, SEC filings, investor presentations), peer-reviewed literature (PubMed, PMC), industry analyses, and financial databases. Full reference list available in markdown version.